Fri.Dec 20, 2024

article thumbnail

U.S. FDA Clears Avita Medical’s Cohealyx for Healing Full-thickness Wounds

The Dermatology Digest

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Cohealyx, a new collagen-based dermal matrix designed for tissue integration and revascularization to facilitate wound healing. Branded by AVITA Medical and co-developed with Regenity Biosciences, Cohealyx may reduce treatment timelines, and improve patient outcomes in the treatment of full-thickness wounds.

article thumbnail

How OJM Group Can Help Dermatologists Reach Their Financial Goals in 2025 and Beyond

Dermatology Times

Trust and transparency are key in physician wealth management, according to David Mandell, JD, MBA.

article thumbnail

Thyroid Health in Perimenopause and Menopause: What Every Woman Needs to Know

Alison Bladh

Thyroid Health in Perimenopause and Menopause: What Every Woman Needs to Know For years, the narrative around menopause has been consistent: its a challenging but natural phase in a womans life that brings with it a host of symptoms like fatigue, weight gain, brain fog, and mood swings. And while menopause undoubtedly has a significant impact on our bodies, its not always the sole culprit behind these symptoms.

Diet 52
article thumbnail

Dermatology Times December 2024 Recap

Dermatology Times

Dermatology Times is looking back on the top stories in dermatology from the month of December.

article thumbnail

The Year of the Glow-Up

Salon Today

The 21st century is turning 25, and consumers are seeking products and services that make them look like they are, too. We list the top five aesthetic trends for 2025.

59
article thumbnail

InflaRx Advances INF904 for CSU and HS with Phase 2a Study

Dermatology Times

The company stated INF904 disrupts inflammatory pathways with over 90% effectiveness, based on Phase 1 data.

45

More Trending

article thumbnail

Dispelling Skin Myths: A New Era of Preventative Care for Anti-Aging, Cleansing, and Sunscreen

Dermatology Times

Renata Block, MMS, PA-C; Ted Lain, MD, MBA, FAAD; Zoe Diana Draelos, MD; and Cheri Frey, MD, FAAD, bust common skin care myths in a Dermatology Times custom video series.

article thumbnail

U.S. Dermatology Partners Welcomes Casey Busmente, PA-C to Sterling, Colorado

US Dermatologt Partners

Sterling, Colorado U.S. Dermatology Partners is pleased to welcome Casey Busmente , PA-C totheir Sterling, Colorado office. Certified Physician Assistant Casey Busmente Joins U.S. Dermatology Partners at their Office in Sterling, Colorado Casey Busmente graduated with a Bachelor of Science degree from the University of South Dakota and earned her Physician Assistant degree from the University of Colorado at the Denver Anschutz Medical Campus.

article thumbnail

Interview Intersection: Expert Interviews From December 2024

Dermatology Times

Dermatology Times is recapping our top expert interviews from the month of December.

article thumbnail

Should I Charge for No-Shows and Late Cancellations?

Style Seat - Business Growth

Every stylist has to deal with no-shows and late cancellations for scheduled appointments. The average beauty professional faces one to two no-shows a week adding up to nearly $5,000 missed income each year. Unfortunately, many professionals are afraid to hold their clients accountable with a no-show fee. Your clients expect you to show up on time shouldn’t you expect the same from them?

article thumbnail

Understanding Patient Comorbidities and Burden of Disease in Prurigo Nodularis

Dermatology Times

A panelist discusses how prurigo nodularis is a chronic inflammatory skin condition that disproportionately affects middle-aged adults and those with immune disorders, causing intensely pruritic nodules that significantly impact quality of life through both physical discomfort and psychological distress.

36
article thumbnail

Advances in Systemic Treatment Options for Prurigo Nodularis

Dermatology Times

A panelist discusses how the treatment landscape for prurigo nodularis (PN) has evolved from primarily using topical therapies and off-label systemic medications to incorporating FDA-approved targeted biologics such as dupilumab and nemolizumab, which have demonstrated significant efficacy in reducing both the itchiness and nodular lesions.